Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe now
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About Hardman & Co.
Case Studies
Our team
News & events
Contact us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Subscribe now
Receive our latest research as soon as it is published
Investment Research & Analysis
Detailed company analysis created for specifically for investors
Tax Enhanced Services
Product reports for investors and advisors
Bespoke Services
Services for clients with specific needs
About Hardman & Co.
We are the longest-established commissioned research provider. Read our story
Case Studies
We help a wide range of clients with different needs. Read what they say about us
Our Team
Meet the Hardman & Co team members
EVENT -
Hardman & Co November Investor Forum – Registration open now
Latest Corporate research
Our research can still be accessed for free under MIFID II.
Find out more >
All Corporate research
- Update
- Monthly Report
- Sector Report
- Initiation
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Renewables
Services
Technology
Utilities
list companies
Avacta Group plc
Life Sciences
De-risking of the partnership with Moderna
By
Dr Martin Hall
08 May 2017
Avacta Group plc
Life Sciences
Bringing forward the Affimer technology
By
Dr Martin Hall
05 May 2017
Stay up-to-date with the latest research
Sign up to our newsletter
Avacta Group plc
Life Sciences
Another important box ticked
By
Dr Martin Hall
12 Apr 2017
City of London Investment Group
Financials
Rising markets and improved performance
By
Dr Brian Moretta
12 Apr 2017
Redx Pharma
Life Sciences
CARB-X – new strategic collaboration
By
Dr Martin Hall
03 Apr 2017
Oxford BioMedica
Life Sciences
Initiation: Delivering commercial gene-therapy vector
By
Dr Dorothea Hill
31 Mar 2017
Arbuthnot Banking Group Plc
Financials
History is repeating itself
By
Mark Thomas
28 Mar 2017
Diurnal Group Plc
Life Sciences
Commercial and development progresses
By
Dr Martin Hall
27 Mar 2017
Chamberlin Plc
Industrial
Turbo-charging into a new growth phase
By
Paul Singer
21 Mar 2017
Avacta Group plc
Life Sciences
Low response would be positive!
By
Dr Gregoire Pave
21 Mar 2017
Burford Capital
Financials
Another positive verdict
By
Dr Brian Moretta
20 Mar 2017
Prev
1
...
28
29
30
31
32
Next
